300255 Stock Overview
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥19.08 |
| 52 Week High | CN¥25.88 |
| 52 Week Low | CN¥7.56 |
| Beta | 0.046 |
| 11 Month Change | -16.17% |
| 3 Month Change | 88.35% |
| 1 Year Change | 50.95% |
| 33 Year Change | 144.62% |
| 5 Year Change | 269.05% |
| Change since IPO | 123.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300255 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -9.6% | -1.8% | -2.6% |
| 1Y | 50.9% | -7.0% | 4.2% |
Return vs Industry: 300255 exceeded the CN Pharmaceuticals industry which returned -6% over the past year.
Return vs Market: 300255 exceeded the CN Market which returned 4.6% over the past year.
Price Volatility
| 300255 volatility | |
|---|---|
| 300255 Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300255's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300255's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,410 | Hao Cai | www.hbcsbio.com |
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. It offers crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadri heparin calcium API, nandroparin calcium injection, and dalteparin sodium API and injection.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Fundamentals Summary
| 300255 fundamental statistics | |
|---|---|
| Market cap | CN¥17.54b |
| Earnings (TTM) | -CN¥844.59m |
| Revenue (TTM) | CN¥1.05b |
16.6x
P/S Ratio-20.8x
P/E RatioIs 300255 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300255 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.05b |
| Cost of Revenue | CN¥1.59b |
| Gross Profit | -CN¥536.35m |
| Other Expenses | CN¥308.24m |
| Earnings | -CN¥844.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -50.85% |
| Net Profit Margin | -80.07% |
| Debt/Equity Ratio | 92.6% |
How did 300255 perform over the long term?
See historical performance and comparison